Adjuvant radiotherapy halved recurrence risk after complete resection of atypical meningioma
ROAM/EORTC-1308 improved 5-year disease-free survival from 64.3% to 79.9% after complete resection of WHO grade 2 meningioma.
Tag
RCT
Benzydamine spray reduced severe mucositis in a randomized head and neck pilot
Grade ≥3 mucositis at week 6 occurred in 11.1% with benzydamine versus 70.6% with standard care.
Hypofractionated salvage radiotherapy did not improve biochemical control after prostatectomy
Four-year biochemical control was similar with 65 Gy in 26 fractions and 66 Gy in 33 fractions, while gastrointestinal toxicity was higher.
Long-course chemoradiotherapy improved early organ preservation in STAR-TREC
Twelve-month TME-free survival was 78.5% with long-course chemoradiotherapy versus 60.6% with short-course radiotherapy in early rectal cancer.
Lithium mouthwash reduced severe oral mucositis during head and neck radiotherapy
Lithium mouthwash reduced severe oral mucositis from 52.1% to 34.2% in a randomized phase II head and neck radiotherapy trial.
Induction TPF did not improve three-year PFS over adjuvant PF in locally advanced NPC
Three-year PFS was 79.0% with induction TPF versus 74.5% with adjuvant PF, with substantially different toxicity profiles.
Six-fraction chemoradiation worsened survival in newly diagnosed glioblastoma
Six-fraction chemoradiation shortened median survival from 21 to 13 months and substantially increased radiation necrosis compared with standard treatment.
SUPREMO radiotherapy modestly worsened chest wall symptoms without broader quality-of-life loss
EXCERPT At five years, chest wall radiotherapy modestly worsened local symptoms but did not significantly affect overall quality of life or major functional domains.
Calling it “radiation therapy” reduced treatment preference compared with “radiotherapy”
In a randomized US survey, “radiation therapy” reduced selection of the same treatment by 8.3 percentage points versus “radiotherapy.”
Short-course total neoadjuvant therapy improved five-year survival in STELLAR
Five-year overall survival was 78.1% with short-course total neoadjuvant therapy versus 69.7% with long-course chemoradiotherapy.
Three-week locoregional breast radiotherapy was noninferior for arm lymphedema
40 Gy in 15 fractions did not increase three-year arm lymphedema or compromise recurrence and mortality outcomes compared with 50 Gy.
Early neuropsychological care did not improve three-month quality of life in brain metastases
ATHENA did not improve FACT-Br scores at three months, although an exploratory nine-month analysis favoured neuropsychological integration.
First-line temozolomide and radiotherapy produced similar survival in high-risk low-grade glioma
After 13 years, first-line temozolomide and radiotherapy produced similar progression-free and overall survival across molecularly classified low-grade gliomas.
Weekly cisplatin remained non-inferior in postoperative head and neck chemoradiotherapy
Weekly cisplatin remained non-inferior to three-weekly cisplatin at five years in postoperative high-risk head and neck chemoradiotherapy.